1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Defence Therapeutics Inc.
  6. News
  7. Summary
    DTC   CA24463V1013

DEFENCE THERAPEUTICS INC.

(DTC)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Defence Therapeutics Inc. Begins Ind-Enabling Testing of its Accutox Lead Compound Against Breast Cancer

01/10/2022 | 07:30am EDT

Defence Therapeutics Inc. (‘Defence’ or the ‘Company’) announced the start of its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited prior to initiate its Phase I trial in breast cancer patients. Eurofins Advinus Limited is a leading Drug Discovery and Development Contract Research Organization (CRO) with 30 years of experience testing regulated products under Good Laboratory Practice (GLP). With 400 employees, 80 full Preclinical IND packages completed and over 20,000 GLP Toxicology studies with the full range of required toxicology studies, Eurofins Advinus is one of the most experienced Drug Development Contract Research Organisation. Eurofins has been mandated by Defence to complete all final GLP studies required by the FDA and Health Canada on its lead AccuTOXTM molecule. The studies will be conducted on both rats (rodent) and dogs (non-rodents) to identify the maximum tolerated dose in addition to evaluate the pharmacokinetic and toxicology profile of the lead compound. According to Fortune Business Insights, the Global Breast Cancer Therapeutics Market, which stood at USD 17.8 Billion in 2018, will reach USD 38.5 Billion by the end of 2026, which would represent a CAGR of 10.2% between 2018 and 2026. The pre-clinical studies conducted by the Defence team on mice revealed how potent is the AccumTM molecule at inhibiting tumor cell growth both in vitro and in vivo. In addition, AccumTM was shown to elicit additive effects in animals when used in conjunction with immune-checkpoint inhibitors such as CTLA-4 and PD-1, two antibodies currently being used in the oncology clinic to treat cancer patients.


© S&P Capital IQ 2022
All news about DEFENCE THERAPEUTICS INC.
05/18Defence?s novel accuvac-pte7 vaccine shows complete protection from cervical cancer
EQ
05/18Defence Therapeutics Inc.'s Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from C..
CI
04/07Defence therapeutics announces issuance of a u.s. patent covering its pioneering vaccin..
EQ
03/22DEFENCE THERAPEUTICS : An anti-cancer solutions platform company advancing its versatile a..
EQ
03/22Defence Therapeutics Inc. Provides an Overview of Its Current Research and Development ..
CI
02/28Defence Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
02/28DEFENCE THERAPEUTICS INC. : Defence releases peer-reviewed publication of its preclinical ..
EQ
02/28Defence Therapeutics Inc. Releases Peer-Reviewed Publication of Its Preclinical Data on..
CI
02/16DEFENCE THERAPEUTICS INC. : Defence retains cato sms to advise on its phase i clinical tri..
EQ
01/26DEFENCE THERAPEUTICS INC. : Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) acti..
EQ
More news
Financials
Sales 2021 - - -
Net income 2021 -2,86 M -2,23 M -2,23 M
Net cash 2021 5,45 M 4,25 M 4,25 M
P/E ratio 2021 -65,6x
Yield 2021 -
Capitalization 119 M 92,4 M 92,4 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float 93,9%
Chart DEFENCE THERAPEUTICS INC.
Duration : Period :
Defence Therapeutics Inc. Technical Analysis Chart | DTC | CA24463V1013 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,25 CAD
Average target price 11,02 CAD
Spread / Average Target 239%
Managers and Directors
Sébastien Plouffe President, Chief Executive Officer & Director
P. Joseph Meagher Chief Financial Officer & Director
Raimar Löbenberg Chairman
Simon Beaudoin Chief Technology & Science Officer
Moutih Rafei Director & VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
DEFENCE THERAPEUTICS INC.-39.81%92
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567